The Middle East Health Journal
SEE OTHER BRANDS

Catch up with healthcare and wellness news from the Middle East

The Middle East Health Journal: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Health Journal.

Press releases published on June 5, 2025

ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders

ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders

PORTLAND, Maine, June 05, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the …

Philips Foundation 2024 Annual Report: expanding access to quality healthcare for 46.5 million people

Philips Foundation 2024 Annual Report: expanding access to quality healthcare for 46.5 million people

In 2024, Philips Foundation initiated 22 new projects and 5 new impact investments expanding its impact and reach in innovative healthcare delivery to India and South America Celebrating a decade of impact with strong progress towards the Foundation’s 2030 …

MUSE Microscopy, Inc. Welcomes Dr. Derek C. Welch to Board of Directors, Appoints Him Chair of Science & Technology Committee

MUSE Microscopy, Inc. Welcomes Dr. Derek C. Welch to Board of Directors, Appoints Him Chair of Science & Technology Committee

IRVINE, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- MUSE Microscopy, Inc., a pioneer in digital pathology innovation, proudly announces the appointment of Dr. Derek C. Welch, MD, FCAP, to its Board of Directors. Dr. Welch, the President and Chief Medical …

Cutest Pets on Parliament Hill 2025: Winners Unveiled at Purr-fectly Playful Pet Gala

Cutest Pets on Parliament Hill 2025: Winners Unveiled at Purr-fectly Playful Pet Gala

OTTAWA, Ontario, June 05, 2025 (GLOBE NEWSWIRE) -- It was paws-itively unforgettable at the 3rd Annual Cutest Pets on Parliament Hill awards celebration, where the winning pets of 2025 were officially crowned at a lively, pet-themed gala hosted by the …

Les animaux de compagnie les plus mignons sur la Colline du Parlement 2025 : Les gagnants sont dévoilés lors d’un gala où les vedettes portaient de riches fourrures

Les animaux de compagnie les plus mignons sur la Colline du Parlement 2025 : Les gagnants sont dévoilés lors d’un gala où les vedettes portaient de riches fourrures

OTTAWA, Ontario, 05 juin 2025 (GLOBE NEWSWIRE) -- La troisième cérémonie annuelle de remise des prix pour le concours « Les animaux de compagnie les plus mignons sur la Colline du Parlement » a été mémorable. Les gagnants de 2025 ont été officiellement …

Osivax Announces Last Patient Last Visit  in Phase 2a Trial Evaluating a Booster Dose of Broad-Spectrum Influenza Vaccine OVX836 s release

Osivax Announces Last Patient Last Visit in Phase 2a Trial Evaluating a Booster Dose of Broad-Spectrum Influenza Vaccine OVX836 s release

Final results expected in H2 2025 Lyon, France – June 5, 2025 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating respiratory viruses, today announced that all participants have completed …

Merus N.V. gibt geplantes öffentliches Zeichnungsangebot von Stammaktien bekannt

Merus N.V. gibt geplantes öffentliches Zeichnungsangebot von Stammaktien bekannt

UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts, June 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) („Merus“, das „Unternehmen“, „wir“ und „unser“), ein Onkologieunternehmen, das innovative, multispezifische Antikörper in voller Länge und …

Merus N.V. annonce une offre publique de souscription d’actions ordinaires

Merus N.V. annonce une offre publique de souscription d’actions ordinaires

UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 05 juin 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS) (« Merus », la « Société », « nous » et « notre »), une société spécialisée dans l’oncologie qui développe des anticorps multispécifiques innovants …

Oculis Publishes Results of 2025 Annual General Meeting

Oculis Publishes Results of 2025 Annual General Meeting

ZUG, Switzerland, June 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), today announced the results from its 2025 Annual General Meeting held on June 4, 2025 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, …

Press release: Sanofi Launches 2025 Global Employee Stock Purchase Plan

Press release: Sanofi Launches 2025 Global Employee Stock Purchase Plan

Sanofi Launches 2025 Global Employee Stock Purchase Plan Paris, June 5, 2025. Sanofi’s global employee shareholder plan, Action 2025, opens on June 10, 2025, to around 70,000 employees in 55 countries. Now in its 11th year, the program demonstrates the …

Communiqué de presse : Sanofi lance son plan mondial 2025 d’actionnariat salarié

Communiqué de presse : Sanofi lance son plan mondial 2025 d’actionnariat salarié

Sanofi lance son plan mondial 2025 d’actionnariat salarié Paris, le 5 juin 2025. Sanofi lance Action 2025, son plan mondial d’actionnariat salarié, qui sera ouvert le 10 juin 2025 à environ 70 000 salariés dans 55 pays. Ce plan, qui entre dans sa onzième …

Philips announces exchange ratio for 2024 dividend

Philips announces exchange ratio for 2024 dividend

June 5, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), today announced that the exchange ratio for the dividend for the year 2024 is 1 new common share for every 23.6353 existing common shares. This ratio was based on the volume …

CancerVax Achieves Major Milestone with Successful Creation of Cell Targeting Nanoparticle

CancerVax Achieves Major Milestone with Successful Creation of Cell Targeting Nanoparticle

Lehi, June 05, 2025 (GLOBE NEWSWIRE) -- Lehi, Utah – June 5, 2025 – CancerVax, Inc., the developer of a breakthrough universal cancer treatment (UCT) platform designed to use the body’s immune system to treat cancer, today announced the successful creation …

Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)

Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)

HYDERABAD, India and REYKJAVIK, Iceland, June 05, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide (“Alvotech”), and Dr. Reddy’s …

Juvenescence acquires AI drug discovery company Ro5 to boost R&D capabilities and drive pipeline of medicines to extend healthy lifespan

Juvenescence acquires AI drug discovery company Ro5 to boost R&D capabilities and drive pipeline of medicines to extend healthy lifespan

Ro5 Inc. acquisition enhances artificial intelligence/machine learning drug discovery capabilities Strategic addition strengthens Juvenescence’s AI-enabled therapeutics pipeline and supports partnership with M42 (Mubadala) Acquisition follows $76m Series B …

Starke Verkaufszahlen für Cresemba® (Isavuconazol) in der Region Asien-Pazifik und China lösen weitere Meilensteinzahlung an Basilea aus

Starke Verkaufszahlen für Cresemba® (Isavuconazol) in der Region Asien-Pazifik und China lösen weitere Meilensteinzahlung an Basilea aus

Allschwil, 05. Juni 2025 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren Infektionen durch Bakterien oder Pilze erkrankt sind, gab …

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers further milestone payment to Basilea

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers further milestone payment to Basilea

Allschwil, Switzerland, June 05, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued …

 AstriVax Therapeutics Initiates Clinical Development of AVX70371, a Hepatitis B immunotherapy using Launch-iT technology

AstriVax Therapeutics Initiates Clinical Development of AVX70371, a Hepatitis B immunotherapy using Launch-iT technology

Third asset to advance into clinical trials, validating broad potential of Launch-iT platform All subjects treated with first dose of AVX70371 Launch-iT, as part of multiple dosing schedule Potential first-in-class treatment that could form part of …

Addex to Present Positive GABAB PAM Chronic Cough Data at the 10th American Cough Conference 

Addex to Present Positive GABAB PAM Chronic Cough Data at the 10th American Cough Conference 

Geneva, Switzerland, June 5, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that …

Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million

Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million

THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED, OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, RUSSIA, BELARUS, OR ANY …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service